Top Approvals Stories


Comment & Analysis »

GlobalData Healthcare

Could Novartis’ longer-acting anti-VEGF Drug, RTH258, offset Lucentis’ loss to Eylea?

On June 20, Novartis announced that both of its head-to-head pivotal Phase III trials of RTH258 (brolucizumab), HAWK and HARRIER, met the primary endpoint of non-inferior efficacy...

Could Novartis’ longer-acting anti-VEGF Drug, RTH258, offset Lucentis’ loss to Eylea?
GlobalData Healthcare

Fecal transplant-based treatment for C. difficile reaches phase III trials

Fecal transplant-based treatment for C. difficile reaches phase III trials
GlobalData Healthcare

Unpredictable epidemiology necessitates a more empirical approach to Zika and Ebola vaccine development

Unpredictable epidemiology necessitates a more empirical approach to Zika and Ebola vaccine development
GlobalData Healthcare

Highlights from the 2017 ATS Conference – Positive results for Nucala marks strong potential for GSK to win the first approved biologic for eGPA

Highlights from the 2017 ATS Conference – Positive results for Nucala marks strong potential for GSK to win the first approved biologic for eGPA
GlobalData Healthcare

Majority of UC Cases Considered Mild to Moderate

Majority of UC Cases Considered Mild to Moderate

Company Releases »

Pharmaceutical Contract Development, Manufacturing, Packaging and Distribution

Kemwell
Pharmaceutical Contract Development, Manufacturing, Packaging and Distribution

Paediatric Clinical Trials 2016

SMI
Paediatric Clinical Trials 2016

Bioneer Biomarker Services

Bioneer Bioneer Biomarker Services

Disease Models, Biomarkers, Recombinant Proteins and Formulation Services

Bioneer
Disease Models, Biomarkers, Recombinant Proteins and Formulation Services

Kemwell: Keeping You Competitive

Kemwell Kemwell: Keeping You Competitive

Approvals Insights »

Companies »